Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anti-spasticity agents for multiple sclerosis.

D T Shakespeare1, C A Young, M Boggild

  • 1The Walton Centre for Neurology and Neurosurgery, Lower Lane, Liverpool, UK, L9 7LJ. boggil-m@wcnn.co.uk

The Cochrane Database of Systematic Reviews
|October 18, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Association of Health Locus of Control with Clinical and Psychosocial Aspects of Living with Multiple Sclerosis.

Journal of clinical psychology in medical settings·2023
Same author

Prevalence of depression in amyotrophic lateral sclerosis/motor neuron disease: multi-attribute ascertainment and trajectories over 30 months.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2022
Same author

In vitro assessment of the DNA damage and senility of CD117+ stem cells collected from diabetic mice.

European review for medical and pharmacological sciences·2022
Same author

Measuring coping in people with amyotrophic lateral sclerosis using the Coping Index-ALS: A patient derived, Rasch compliant scale.

Journal of the neurological sciences·2021
Same author

De Novo Assembly and Characterization of Tall Fescue Transcriptome under Water Stress.

The plant genome·2020
Same author

Treatment of MOG antibody associated disorders: results of an international survey.

Journal of neurology·2020
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Evidence for anti-spasticity agents in multiple sclerosis (MS) is limited. Current studies lack validated measures, preventing recommendations for effective treatment of MS spasticity.

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Trials

Background:

  • Spasticity is a prevalent and debilitating symptom in multiple sclerosis (MS).
  • It significantly impacts patient quality of life, causing pain, spasms, functional loss, and care challenges.
  • Existing oral and parenteral medications offer varied approaches to management.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of anti-spasticity medications in MS patients.
  • To compare the effectiveness of different agents used for spasticity management.

Main Methods:

  • Systematic review of randomized controlled trials (RCTs) identified through comprehensive literature searches.
  • Inclusion criteria specified double-blind, placebo-controlled or comparative studies of at least seven days duration.

Related Experiment Videos

  • Data extraction by two independent reviewers; meta-analysis was precluded by data limitations.

    • Main Results:

    • Twenty-three placebo-controlled and thirteen comparative studies met the criteria, involving agents like baclofen, dantrolene, and tizanidine.
    • Few studies utilized validated scales like the Ashworth scale, with limited statistically significant findings.
    • Outcome measures for spasms, symptoms, and functional assessments were often unvalidated or inconclusive.

    Conclusions:

    • The current evidence base for anti-spasticity agents in MS is insufficient to guide clinical prescribing.
    • Further research is needed to understand the underlying mechanisms of upper motor neuron syndrome.
    • Development of sensitive and validated measures for spasticity assessment is crucial.